Entry Detail


General Information

Database ID:TRD05525
Confidence:Very High
Contents:>> tsRNA Information
>> tsRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference



tsRNA Information

tsRNA Name:tsRNA-0032
tsRNA Type:N/A
Amino acid and Anticodon:N/A
Sequence:N/A
Related Target:PKM2
Predicted Target:N/A
External Links:
MINTbase ID:N/A
tRFdb ID:N/A



tsRNA Association Statistics

Total Associated Disease Number:1
More Information
Network:
(Display the first 15 nodes)



Disease Information

 MeSHDisease Ontology
Disease ID:N/ADOID:12399
Disease Name:N/Apathological lymphangiogenesis
Category:MeSHDisease Ontology
Type:N/Adisease of mental health
Define:N/AAn impulse control disorder that involves the uncontrollable impulse to gamble, irrespective of the interference the behaviour has on the individual's life.
Alias:N/ACompulsive gambling



Disease Association Statistics

Total Associated tsRNA Number:1
More Information
Network:
(Display the first 15 nodes)



Evidence Support

Strong Evidence:RT-PCR//Western blot//Transfection//RIP//Scratch wound healing assay
Weak Evidence:High-throughput sequencing



Reference

[1] PubMed ID:39870617
Disease Name:pathological lymphangiogenesis
Tissue:Eye
Dysfunction Pattern:N/A
Validated Method:RT-PCR//Western blot//Transfection//RIP//Scratch wound healing assay//High-throughput sequencing
Description:TsRNA-0032 expression is down-regulated during inflammatory stress Pathological conditions such as inflammation or trauma can induce lymphatic vessel growth into the corneal center
Comparision:Disease VS Control
Mechanism:In conclusion, this study identifies tsRNA-0032 as a critical regulator of LEC function and lymphangiogenesis. We demonstrate that tsRNA-0032 significantly inhibits LEC proliferation, migration, tube formation, and sprouting in vitro. These inhibitory effects were further validated by in vivo model. Mechanistically, tsRNA-0032 was found to interact with Ago2 and target the glycolytic enzyme PKM2, thereby disrupting glycolytic reprogramming in LECs. These findings underscore the therapeutic potential of targeting tsRNA-0032/PKM2 axis in diseases involving pathological lymphangiogenesis.